Bumetanide, Oral Tablet

Bumetanide (buprenorphine) is a long acting opioid analgesic with low abuse potential. It was approved by the FDA in 1998 for the treatment of pain associated with cancer chemotherapy, endometriosis, and other conditions. Its effectiveness has been well established in clinical trials, but its use has declined due to concerns over abuse liability and addiction risk.

The drug is classified as a Schedule III controlled substance because it has high potential for abuse and no accepted medical use in the United States. Buprenorphine is available only through prescription from a physician or health care provider.

Side Effects of Bumetanide:

In addition to the risks associated with any medication, there are some possible side effects of buprenorphine that may occur when taken by mouth. These include:

Decreased appetite

Dizziness

Nausea/vomiting

Vomiting/diarrhea (sometimes fatal)

These side effects may last for several days after stopping the medication. They usually go away within a few weeks without further treatment. If they do not disappear, see your doctor immediately.

There have been reports of death related to these symptoms.

Like other opioids, side effects are much more likely when this drug is taken in high doses.

There is a risk of a severe allergic reaction with any opioid medication. If you notice a rash, hives, breathing difficulties, or swelling of the lips or throat, seek emergency medical attention immediately.

Opiods can also cause problems related to your digestive system (nausea, constipation, stomach pain, loss of appetite). This can become more severe and lead to serious issues such as blockage, infection, or even death.

It is possible, though rare, to become psychologically addicted to this drug. If you find that you are consistently taking more than prescribed or for the feeling that it gives you, you may be addicted. This can happen after just one incidence of taking too much.

It is also more likely if you have a pre-existing history of substance abuse.

Another serious concern is the risk of overdose. Opioid drugs (including this one) can lead to respiratory depression, and the breathing rate drops to a point where the body can no longer sustain life. If this occurs, the person may go unconscious and eventually die.

Death can also occur from the seizure that can sometimes accompany an overdose.

Taking this medication with alcohol or other drugs that also cause respiratory depression may lead to accidental overdose and death. If you have questions about this, be sure to discuss it with your prescribing doctor.

Sources & references used in this article:

Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects by AA Holazox, WA Colburn, JH Gustafson… – Journal of …, 1984 – Elsevier

Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide by DL Davies, AF Lant, NR Millard… – Clinical …, 1974 – Wiley Online Library

Effect of food on the absorption of frusemide and bumetanide in man by JL McCrindle, TC Li Kam Wa, W Barron… – British journal of …, 1996 – Wiley Online Library

Fate of [14C]‐bumetanide in man. by PJ Pentikainen, A Penttila… – British journal of …, 1977 – Wiley Online Library

Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure by JA Cook, DE Smith, LA Cornish… – Clinical …, 1988 – Wiley Online Library

Bioavailability of bumetanide in grossly oedematous patients by GR Bailie, A Grennan, S Waldek – Clinical pharmacokinetics, 1987 – Springer

Some aspects of the clinical pharmacology of bumetanide, a new, potent oral diuretic. by DL Davies, AF Lant, NR Millard, AJ Smith… – British journal of …, 1973 – ncbi.nlm.nih.gov

Bumetanide: a new loop diuretic (Bumex, Roche Laboratories) by CE Halstenson, GR Matzke – Drug intelligence & clinical …, 1983 – journals.sagepub.com